Sarcopenia and Low BMI Linked to High Toxicity and Poorer Survival in NK/T-Cell Lymphoma
A retrospective study highlights how pre-treatment body composition and weight may affect clinical outcomes.
Key takeaways
- In a retrospective study of 347 patients with newly diagnosed extranodal natural killer/T-cell lymphoma, sarcopenia was identified in 32.6% of patients.
- Patients with sarcopenia had significantly higher relative risks of hematological toxicity (1.15) and gastrointestinal toxicity (1.46) compared to those without.
- Sarcopenia was an independent predictor of overall mortality (adjusted hazard ratio of 1.58), but was not a statistically significant predictor of progression-free survival.
- Underweight patients experienced the highest toxicity burden and poorest survival, while overweight patients showed the most favorable outcomes.
- Exploratory analyses indicated that patients presenting with both sarcopenia and low body mass index carried the highest risk of mortality.
A retrospective study analyzed 347 patients with newly diagnosed extranodal natural killer/T-cell lymphoma (ENKTL) to evaluate the impact of sarcopenia and body mass index (BMI) on treatment-related toxicities and survival outcomes. Published in the journal Frontiers in Oncology in July 2026, the study evaluated patients using data from a retrospective cohort.
Sarcopenia was assessed using sex-specific skeletal muscle index thresholds at the third lumbar vertebra level. Patients were also categorized into body mass index groups—underweight, normal weight, or overweight—using Asian-specific criteria. The study investigated how these factors associated with hematological toxicity, gastrointestinal toxicity, overall survival, and progression-free survival.
Out of the 347 patients evaluated, sarcopenia was identified in 113 individuals, which represents 32.6% of the cohort. The analysis showed that sarcopenia was associated with adverse clinical characteristics and significant differences in treatment-related toxicities and overall survival.
What Happened
The retrospective analysis showed that patients with sarcopenia had significantly higher risks of treatment-related toxicities compared to patients without sarcopenia. Specifically, the relative risk for hematological toxicity was 1.15 (95% CI 1.06-1.24, p = 0.001), and the relative risk for gastrointestinal toxicity was 1.46 (95% CI 1.10-1.95, p = 0.009).
Sarcopenia was also associated with inferior overall survival (log-rank p = 0.004). In a multivariable analysis, sarcopenia remained an independent predictor of mortality, showing an adjusted hazard ratio of 1.58 (95% CI 1.10-2.27, p = 0.013). However, sarcopenia was not a statistically significant independent predictor of progression-free survival, showing an adjusted hazard ratio of 1.31 (95% CI 0.93-1.84, p = 0.119).
What The Evidence Shows
When evaluating body mass index, the study categorized patients using Asian-specific criteria. Underweight patients experienced the highest toxicity burden and the poorest survival outcomes. In contrast, overweight patients demonstrated the most favorable outcomes. Exploratory analyses also suggested that patients who had both sarcopenia and a low body mass index experienced the highest risk of mortality.
What We Don't Know Yet
Because this study is a retrospective, observational analysis, it cannot establish a direct cause-and-effect relationship between body composition and patient outcomes. Furthermore, body mass index was categorized according to Asian-specific criteria, which may limit the generalizability of these specific weight-category findings to non-Asian cohorts. The published study does not report other potential limitations, such as details on specific treatment regimens or patient selection.
What Comes Next
The study concludes that incorporating body composition assessment into routine clinical evaluations may improve risk stratification and supportive care in patients with extranodal natural killer/T-cell lymphoma. However, the published source does not report any planned next steps, future clinical trials, or prospective studies to validate these findings or test specific supportive care interventions.
What This Means
The association between sarcopenia, low body mass index, and poorer outcomes suggests that routine physical assessments of body composition could guide clinical management. Evaluating a patient's skeletal muscle index at the third lumbar vertebra level and body mass index prior to treatment could help identify individuals who are highly vulnerable to adverse outcomes. This information could allow healthcare teams to provide targeted supportive care to those at the highest risk.
Original Source
PubMed (NCBI E-utilities): https://pubmed.ncbi.nlm.nih.gov/42591242/
Questions readers ask
- How was sarcopenia measured in this lymphoma study?
- Sarcopenia was evaluated using sex-specific skeletal muscle index thresholds measured at the third lumbar vertebra level. The researchers retrospectively analyzed these thresholds in 347 patients with newly diagnosed extranodal natural killer/T-cell lymphoma.
- Did sarcopenia affect progression-free survival in patients with extranodal natural killer/T-cell lymphoma?
- No, sarcopenia was not a statistically significant independent predictor of progression-free survival. The multivariable analysis showed an adjusted hazard ratio of 1.31 with a p-value of 0.119, which indicates no statistically significant association.
- How did body mass index influence toxicity and survival outcomes?
- Using Asian-specific criteria, underweight patients had the highest treatment-related toxicity burden and the poorest survival outcomes. Conversely, overweight patients had the most favorable outcomes, and those with both sarcopenia and low body mass index had the highest mortality risk.
What this means
The association between sarcopenia, low body mass index, and poorer outcomes suggests that routine physical assessments of body composition could guide clinical management. Evaluating a patient's skeletal muscle index at the third lumbar vertebra level and body mass index prior to treatment could help identify individuals who are highly vulnerable to adverse outcomes. This information could allow healthcare teams to provide targeted supportive care to those at the highest risk.
Limitations and uncertainties
- Because this study is a retrospective, observational analysis, it cannot establish a direct cause-and-effect relationship between body composition and patient outcomes. Furthermore, body mass index was categorized according to Asian-specific criteria, which may limit the generalizability of these specific weight-category findings to non-Asian cohorts. The published study does not report other potential limitations, such as details on specific treatment regimens or patient selection.
